Dermatology
Audio Summaries

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

This phase 1 study investigates the safety and efficacy of anitocabtagene autoleucel (anito-cel), a BCMA-directed CAR T-cell therapy, in patients with relapsed or refractory multiple myeloma who have undergone multiple prior treatments. The results indicate a high response rate (100%) with a significant proportion achieving complete response (79%), while adverse events, particularly cytokine release syndrome and neurotoxicity, were mostly mild. The findings suggest that anito-cel may be a promising treatment option for this challenging patient population.

Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis

The authors aimed to determine whether screening with a multicancer early-detection test, in addition to usual care, reduces the incidence of late-stage cancers (stage III or IV) compared to usual care alone. In a randomized controlled trial involving over 142,000 participants, they found no significant difference in the incidence rates of stage III or IV cancers between the two groups after three screening rounds. While there was a trend towards a lower incidence of stage IV cancers, the results were not conclusive, indicating the need for further follow-up.

Etuvetidigene Autotemcel for the Treatment of Wiskott-Aldrich Syndrome

This study investigates the efficacy and safety of etuvetidigene autotemcel (etu-cel), an autologous gene therapy, for treating Wiskott-Aldrich syndrome, a rare genetic disorder. The results indicate a high overall survival rate of 96% at both 1 and 5 years post-treatment, along with a significant reduction in severe infections and bleeding events after therapy. The findings suggest that etu-cel provides a sustained clinical benefit for patients with this condition.

Clinical Uses of Common Genetic Variants Associated with Common Diseases

The authors investigate why the integration of polygenic risk scores and genomic knowledge into clinical practice for common adult-onset diseases has been slow, despite advancements in genomics and the identification of numerous genetic variants associated with these conditions. They explore potential applications of these scores and pharmacogenomics in improving prevention and treatment strategies as genome sequencing becomes more accessible.

Understanding peripheral arterial disease in the current era

The authors aim to address the underacknowledgment, underdiagnosis, and undertreatment of peripheral arterial disease (PAD) in the context of atherosclerotic cardiovascular disease, highlighting its increasing prevalence and significant mortality rates. They emphasize the need for improved recognition and interdisciplinary measures to enhance patient outcomes and advocate for better integration of preventive care and treatment strategies. This clinical series seeks to inform clinicians and policymakers about the global burden of PAD and effective approaches to manage it.

Current advancements in the care of peripheral arterial disease: modern approaches to medical, endovascular, and surgical treatment

The authors review current advancements in the management of peripheral arterial disease (PAD), particularly focusing on the effectiveness of medical therapy, supervised exercise, and the judicious use of revascularization procedures. They aim to address how to optimize treatment strategies to reduce cardiovascular risks, improve quality of life, and minimize limb loss in patients with varying severity of PAD. The paper highlights the complexities of PAD management due to its multifaceted nature and the potential overuse of invasive interventions.

Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead

This paper aims to address the adverse impacts of peripheral arterial disease (PAD) and the disparities in outcomes among affected populations. The authors highlight the significant individual and societal burdens of PAD, particularly on underserved groups, and propose both short-term and long-term strategies to improve management and access to care, including enhanced awareness and multidisciplinary treatment approaches. The study emphasizes the need for targeted interventions to reduce the prevalence and consequences of PAD, especially in vulnerable communities.

Developing roadmaps for advancing practice, research, and policy in the arts and health

The authors aim to develop actionable roadmaps for integrating the arts into health and wellbeing systems globally, addressing the emerging evidence of arts engagement's health benefits. They propose key strategies, including ensuring universal access to arts opportunities, implementing population-level approaches to tackle health inequities, and fostering clinical innovation in arts therapies. Additionally, they highlight the importance of cross-sector collaboration and investment to support these initiatives.

Precision prevention and early detection: framework for a new clinical cancer control pathway

The authors explore how precision prevention and early detection (PPED) can improve cancer control by identifying individuals at elevated risk and tailoring interventions accordingly. They emphasize the importance of both escalating preventive care for high-risk individuals and de-escalating interventions for low-risk individuals, while also highlighting the need for a robust health-system infrastructure to support ongoing prevention efforts. The paper addresses the challenge of enhancing cancer survival rates through better screening and preventive strategies.

Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial

The study aimed to evaluate the efficacy and safety of long-acting injectable (LAI) cabotegravir-rilpivirine compared to daily oral antiretroviral therapy (TLD) in adolescents living with HIV who have achieved virological suppression. Results showed that LAI cabotegravir-rilpivirine was not only non-inferior but also superior to TLD in maintaining virological suppression over 96 weeks, with no new safety concerns identified. These findings suggest that LAI cabotegravir-rilpivirine could be a viable maintenance treatment option for this population in sub-Saharan Africa.